Page 1699 - Hematology_ Basic Principles and Practice ( PDFDrive )

Chapter 93 Late Complications of Hematologic Diseases and Their Therapies 1512.e5

ALL survivors: a review and meta-analysis. Blood 126(3):346–353, 192. Hoover DL, Smith LE, Turner SJ, et al: Ophthalmic evaluation of sur-
2015. vivors of acute lymphoblastic leukemia. Ophthalmology 95(2):151–155,
172. Jain N, Brouwers P, Okcu MF, et al: Sex-specific attention problems in 1988.
long-term survivors of pediatric acute lymphoblastic leukemia. Cancer 193. Gurney JG, Ness KK, Rosenthal J, et al: Visual, auditory, sensory,
115(18):4238–4245, 2009. and motor impairments in long-term survivors of hematopoietic
173. Kadan-Lottick NS, Zeltzer LK, Liu Q, et al: Neurocognitive function- stem cell transplantation performed in childhood: results from the
ing in adult survivors of childhood non-central nervous system cancers. Bone Marrow Transplant Survivor study. Cancer 106(6):1402–1408,
J Natl Cancer Inst 102(12):881–893, 2010. 2006.
174. Krull KR, Brinkman TM, Li C, et al: Neurocognitive outcomes decades 194. Holmstrom G, Borgstrom B, Calissendorff B: Cataract in children after
after treatment for childhood acute lymphoblastic leukemia: a report bone marrow transplantation: relation to conditioning regimen. Acta
from the St Jude lifetime cohort study. J Clin Oncol 31(35):4407–4415, Ophthalmol Scand 80(2):211–215, 2002.
2013. 195. Alloin AL, Barlogis V, Auquier P, et al: Prevalence and risk factors of
175. Buizer AI, de Sonneville LM, Veerman AJ: Effects of chemotherapy on cataract after chemotherapy with or without central nervous system
neurocognitive function in children with acute lymphoblastic leukemia: irradiation for childhood acute lymphoblastic leukaemia: an LEA study.
a critical review of the literature. Pediatr Blood Cancer 52(4):447–454, Br J Haematol 164(1):94–100, 2014.
2009. 196. Belkacemi Y, Labopin M, Vernant JP, et al: Cataracts after total body
176. Spiegler BJ, Kennedy K, Maze R, et al: Comparison of long-term irradiation and bone marrow transplantation in patients with acute
neurocognitive outcomes in young children with acute lymphoblastic leukemia in complete remission: a study of the European Group
leukemia treated with cranial radiation or high-dose or very high-dose for Blood and Marrow Transplantation. Int J Radiat Oncol Biol Phys
intravenous methotrexate. J Clin Oncol 24(24):3858–3864, 2006. 41(3):659–668, 1998.
177. Clanton NR, Klosky JL, Li C, et al: Fatigue, vitality, sleep, and neurocog- 197. Bray LC, Carey PJ, Proctor SJ, et al: Ocular complications of
nitive functioning in adult survivors of childhood cancer: a report from bone marrow transplantation. Br J Ophthalmol 75(10):611–614,
the Childhood Cancer Survivor Study. Cancer 117(11):2559–2568, 1991.
2011. 198. Westeneng AC, Hettinga Y, Lokhorst H, et al: Ocular graft-versus-host
178. Kirchhoff AC, Krull KR, Ness KK, et al: Physical, mental, and disease after allogeneic stem cell transplantation. Cornea 29(7):758–763,
neurocognitive status and employment outcomes in the childhood 2010.
cancer survivor study cohort. Cancer Epidemiol Biomarkers Prev 199. Tabbara KF, Al-Ghamdi A, Al-Mohareb F, et al: Ocular findings after
20(9):1838–1849, 2011. allogeneic hematopoietic stem cell transplantation. Ophthalmology
179. Krull KR, Annett RD, Pan Z, et al: Neurocognitive functioning and 116(9):1624–1629, 2009.
health-related behaviours in adult survivors of childhood cancer: a 200. Leung W, Hudson M, Zhu Y, et al: Late effects in survivors of infant
report from the Childhood Cancer Survivor Study. Eur J Cancer leukemia. Leukemia 14(7):1185–1190, 2000.
47(9):1380–1388, 2011. 201. Matz GJ: Aminoglycoside cochlear ototoxicity. Otolaryngol Clin North
180. Matsumoto K, Takahashi S, Sato A, et al: Leukoencephalopathy in Am 26(5):705–712, 1993.
childhood hematopoietic neoplasm caused by moderate-dose metho- 202. Travis LB, Fossa SD, Sesso HD, et al: Chemotherapy-induced periph-
trexate and prophylactic cranial radiotherapy–an MR analysis. Int J eral neurotoxicity and ototoxicity: new paradigms for translational
Radiat Oncol Biol Phys 32(4):913–918, 1995. genomics. J Natl Cancer Inst 106(5):2014.
181. Edelmann MN, Krull KR, Liu W, et al: Diffusion tensor imaging 203. Effinger KE, Migliorati CA, Hudson MM, et al: Oral and dental late
and neurocognition in survivors of childhood acute lymphoblastic effects in survivors of childhood cancer: a Children’s Oncology Group
leukaemia. Brain 137(Pt 11):2973–2983, 2014. report. Support Care Cancer 22(7):2009–2019, 2014.
182. Krull KR, Sabin ND, Reddick WE, et al: Neurocognitive function and 204. Uderzo C, Fraschini D, Balduzzi A, et al: Long-term effects of bone
CNS integrity in adult survivors of childhood hodgkin lymphoma. J marrow transplantation on dental status in children with leukaemia.
Clin Oncol 30(29):3618–3624, 2012. Bone Marrow Transplant 20(10):865–869, 1997.
183. Meyers CA: Neurocognitive dysfunction in cancer patients. Oncology 205. Dahllof G, Barr M, Bolme P, et al: Disturbances in dental development
(Williston Park) 14(1):75–79, discussion 79, 81-72, 85, 2000. after total body irradiation in bone marrow transplant recipients. Oral
184. Kramer JH, Crittenden MR, DeSantes K, et al: Cognitive and adaptive Surg Oral Med Oral Pathol 65(1):41–44, 1988.
behavior 1 and 3 years following bone marrow transplantation. Bone 206. Castellino S, Muir A, Shah A, et al: Hepato-biliary late effects in sur-
Marrow Transplant 19(6):607–613, 1997. vivors of childhood and adolescent cancer: a report from the Children’s
185. Syrjala KL, Artherholt SB, Kurland BF, et al: Prospective neurocognitive Oncology Group. Pediatr Blood Cancer 54(5):663–669, 2010.
function over 5 years after allogeneic hematopoietic cell transplantation 207. Vora A, Mitchell CD, Lennard L, et al: Toxicity and efficacy of
for cancer survivors compared with matched controls at 5 years. J Clin 6-thioguanine versus 6-mercaptopurine in childhood lymphoblastic
Oncol 29(17):2397–2404, 2011. leukaemia: a randomised trial. Lancet 368(9544):1339–1348, 2006.
186. Andrykowski MA, Altmaier EM, Barnett RL, et al: Cognitive dys- 208. De Bruyne R, Portmann B, Samyn M, et al: Chronic liver disease
function in adult survivors of allogeneic marrow transplantation: related to 6-thioguanine in children with acute lymphoblastic leukae-
relationship to dose of total body irradiation. Bone Marrow Transplant mia. J Hepatol 44(2):407–410, 2006.
6(4):269–276, 1990. 209. Broxson EH, Dole M, Wong R, et al: Portal hypertension develops in
187. Harder H, Cornelissen JJ, Van Gool AR, et al: Cognitive function- a subset of children with standard risk acute lymphoblastic leukemia
ing and quality of life in long-term adult survivors of bone marrow treated with oral 6-thioguanine during maintenance therapy. Pediatr
transplantation. Cancer 95(1):183–192, 2002. Blood Cancer 44(3):226–231, 2005.
188. Syrjala KL, Dikmen S, Langer SL, et al: Neuropsychologic changes 210. Stork LC, Matloub Y, Broxson E, et al: Oral 6-mercaptopurine
from before transplantation to 1 year in patients receiving myeloablative versus oral 6-thioguanine and veno-occlusive disease in children with
allogeneic hematopoietic cell transplant. Blood 104(10):3386–3392, standard-risk acute lymphoblastic leukemia: report of the Children’s
2004. Oncology Group CCG-1952 clinical trial. Blood 115(14):2740–2748,
189. Meyers CA, Weitzner M, Byrne K, et al: Evaluation of the neurobe- 2010.
havioral functioning of patients before, during, and after bone marrow 211. Rawat D, Gillett PM, Devadason D, et al: Long-term follow-up of
transplantation. J Clin Oncol 12(4):820–826, 1994. children with 6-thioguanine-related chronic hepatoxicity following
190. Padovan CS, Yousry TA, Schleuning M, et al: Neurological and neuro- treatment for acute lymphoblastic leukaemia. J Pediatr Gastroenterol
radiological findings in long-term survivors of allogeneic bone marrow Nutr 53(5):478–479, 2011.
transplantation. Ann Neurol 43(5):627–633, 1998. 212. Cesaro S, Petris MG, Rossetti F, et al: Chronic hepatitis C virus infec-
191. Elliott AJ, Oakhill A, Goodman S: Cataracts in childhood leukaemia. tion after treatment for pediatric malignancy. Blood 90(3):1315–1320,
Br J Ophthalmol 69(6):459–461, 1985. 1997.